08:26 AM EDT, 03/18/2024 (MT Newswires) -- Arch Biopartners Inc. ( ACHFF ), (ARCH.V) on Monday announced that it has published a peer reviewed paper in the British Medical Journal Open (BMJ Open) detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients infected with SARS-CoV-2 virus. LSALT peptide is a DPEP-1 inhibitor and Arch's lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs, and liver.

According to the statement, the results of the Phase II trial provided first-ever evidence validating DPEP-1 as a mediator of organ inflammation and therapeutic target in humans. LSALT peptide was also well tolerated with no safety issues related to the drug.

New biomarker data for LSALT peptide was disclosed for the first time in the BMJ Open publication. The new data provides more scientific rationale for Arch to advance LSALT peptide to prevent leukocyte recruitment and organ inflammation for other indications, including a larger Phase II trial targeting cardiac surgery-associated AKI, which recently began recruiting patients.